Francis M Mondimore
Overview
Explore the profile of Francis M Mondimore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panagiotaropoulou G, Georgii Hellberg K, Coleman J, Seok D, Kalman J, Mitchell P, et al.
Br J Psychiatry
. 2025 Jan;
1-12.
PMID: 39806801
Background: Accurate diagnosis of bipolar disorder (BPD) is difficult in clinical practice, with an average delay between symptom onset and diagnosis of about 7 years. A depressive episode often precedes...
2.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Int J Bipolar Disord
. 2024 Jun;
12(1):20.
PMID: 38865039
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
3.
Panagiotaropoulou G, Georgii Hellberg K, Coleman J, Seok D, Kalman J, Mitchell P, et al.
medRxiv
. 2024 Feb;
PMID: 38410442
Background: Accurate diagnosis of bipolar disorder (BD) is difficult in clinical practice, with an average delay between symptom onset and diagnosis of about 7 years. A key reason is that...
4.
Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, Alda M, et al.
Transl Psychiatry
. 2024 Feb;
14(1):109.
PMID: 38395906
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
5.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Res Sq
. 2023 Dec;
PMID: 38077040
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
6.
Amare A, Thalamuthu A, Schubert K, Fullerton J, Ahmed M, Hartmann S, et al.
Mol Psychiatry
. 2023 Jul;
28(12):5251-5261.
PMID: 37433967
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not...
7.
Coombes B, Millischer V, Batzler A, Larrabee B, Hou L, Papiol S, et al.
Complex Psychiatry
. 2022 Nov;
7(3-4):80-89.
PMID: 36408127
Response to lithium varies widely between individuals with bipolar disorder (BD). Polygenic risk scores (PRSs) can uncover pharmacogenomics effects and may help predict drug response. Patients ( = 2,510) with...
8.
Schubert K, Thalamuthu A, Amare A, Frank J, Streit F, Adl M, et al.
Transl Psychiatry
. 2022 Jul;
12(1):278.
PMID: 35817769
No abstract available.
9.
Cearns M, Amare A, Schubert K, Thalamuthu A, Frank J, Streit F, et al.
Br J Psychiatry
. 2022 May;
221(2):494.
PMID: 35505515
No abstract available.
10.
Cearns M, Amare A, Schubert K, Thalamuthu A, Frank J, Streit F, et al.
Br J Psychiatry
. 2022 Feb;
220(4):219-228.
PMID: 35225756
Background: Response to lithium in patients with bipolar disorder is associated with clinical and transdiagnostic genetic factors. The predictive combination of these variables might help clinicians better predict which patients...